Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
- 1 April 2020
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 192, 112158
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 106-2113-M-038 -002, 107-2113-M-038 -001, 108-2320-B-038-056)
This publication has 15 references indexed in Scilit:
- A perspective on multi‐target drug discovery and design for complex diseasesClinical and Translational Medicine, 2018
- The therapeutic potential of resveratrol: a review of clinical trialsnpj Precision Oncology, 2017
- Histone Deacetylase Inhibitors as Anticancer DrugsInternational Journal of Molecular Sciences, 2017
- The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug DesignCurrent Medicinal Chemistry, 2016
- Combine and conquer: challenges for targeted therapy combinations in early phase trialsNature Reviews Clinical Oncology, 2016
- Resveratrol and cancer: Challenges for clinical translationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Tubulin inhibitors: a patent reviewExpert Opinion on Therapeutic Patents, 2013
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001